Akums Drugs & Pharma IPO: Share Allotment Finalised, GMP Hints Strong Listing; Check Status

The initial public offering (IPO) of Akums Drugs and Pharmaceuticals Ltd has garnered healthy attention and strong demand from investors, marking a successful subscription phase. This article delves into the key details of the Akums Drugs IPO, from the subscription status to the allotment process and its implications for investors.

Akums Drugs and Pharmaceuticals IPO opened for bidding on July 30 and closed on August 1. The subscription figures highlight the strong interest from various investor categories. According to the data available, the IPO was subscribed 63.56 times overall, indicating a robust demand for the shares. Specifically, the retail individual investors (RIIs) category saw a subscription of 21.30 times, while the non-institutional investors (NII) category was subscribed 42.21 times. The most notable interest came from qualified institutional buyers (QIBs), with a subscription of 90.09 times.

The allotment date for Akums Drugs and Pharmaceuticals IPO is set for August 2, with the shares expected to be credited to successful bidders' demat accounts by August 5. For those who did not receive an allotment, refunds will be processed on the same day. The company's shares are slated to be listed on both BSE and NSE on August 6.

Investors can check their IPO allotment status online through the BSE website or the IPO registrar's portal, Link Intime India Private Ltd.

Visit the IPO registrar website at Link Intime India Private Ltd.
Select 'Akums Drugs and Pharmaceuticals Limited' from the dropdown menu.
Choose the appropriate identification option (PAN, application number, DP/Client ID, or account number/IFSC).
Enter the required details.
Click on 'Submit' to view the allotment status.

The grey market premium (GMP) for Akums Drugs IPO has also been noteworthy. As of today, the GMP stands at 141 per share, indicating that the shares are trading at Rs 820 apiece in the grey market, a premium of 20.77% over the issue price of Rs 679 per share.

The price band for the Akums Drugs and Pharmaceuticals IPO was set between Rs 646 and Rs 679 per share. The company successfully raised Rs 1,856.74 crore through the IPO, comprising a fresh issue of 1 crore equity shares amounting to Rs 680 crore and an offer for sale (OFS) of 1.73 crore shares aggregating to Rs 1,176.74 crore. The book-running lead managers for this IPO were ICICI Securities, Axis Bank, Citigroup Global Markets India Private Limited, and Ambit Private Limited.

Akums Drugs and Pharmaceuticals has outlined clear plans for the utilization of the net proceeds from the IPO. The funds will be used for repayment/prepayment of indebtedness of the company and its subsidiaries, funding incremental working capital requirements, pursuing inorganic growth initiatives through acquisitions, and general corporate purposes.

Akums Drugs and Pharmaceuticals is a contract development and manufacturing organization (CDMO) that offers a wide range of pharmaceutical products and services. The company's core business revolves around providing end-to-end product development and manufacturing solutions. In addition to this, Akums is engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

The strong subscription numbers and the high grey market premium suggest that investors have high expectations for Akums Drugs and Pharmaceuticals. The company's use of IPO proceeds to strengthen its financial position and expand its operational capabilities is seen as a positive move. The focus on reducing debt and funding growth initiatives is likely to enhance the company's profitability and market standing.

The Akums Drugs and Pharmaceuticals IPO has concluded with strong investor interest and a strong subscription rate. As the allotment process finalizes and the company prepares for its listing on August 6, investors are keenly watching the developments. The robust grey market premium further adds to the anticipation, reflecting positive market sentiment.